Rockwell Medical (NASDAQ:RMTI) Price Target Lowered to $7.00 at HC Wainwright

Rockwell Medical (NASDAQ:RMTI) had its target price lowered by equities researchers at HC Wainwright from $9.00 to $7.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 211.11% from the stock’s previous close. HC Wainwright also issued estimates for Rockwell Medical’s Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS and Q4 2025 earnings at $0.01 EPS.

A number of other research firms also recently issued reports on RMTI. Rodman & Renshaw began coverage on shares of Rockwell Medical in a report on Thursday, November 14th. They issued a “buy” rating and a $5.00 price objective on the stock. RODMAN&RENSHAW raised shares of Rockwell Medical to a “strong-buy” rating in a report on Thursday, November 14th. Finally, StockNews.com downgraded shares of Rockwell Medical from a “buy” rating to a “hold” rating in a report on Thursday, November 21st.

Rockwell Medical Stock Performance

RMTI opened at $2.25 on Monday. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33. The company has a market cap of $72.72 million, a price-to-earnings ratio of -45.00 and a beta of 1.50. The company’s 50 day moving average is $3.46 and its 200 day moving average is $2.66. Rockwell Medical has a 12-month low of $1.16 and a 12-month high of $5.15.

Hedge Funds Weigh In On Rockwell Medical

Several large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd lifted its holdings in Rockwell Medical by 45.7% during the third quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock valued at $113,000 after purchasing an additional 8,922 shares in the last quarter. Concurrent Investment Advisors LLC purchased a new position in Rockwell Medical during the third quarter valued at approximately $40,000. Verus Capital Partners LLC purchased a new position in Rockwell Medical during the third quarter valued at approximately $51,000. State Street Corp lifted its holdings in shares of Rockwell Medical by 21.5% in the third quarter. State Street Corp now owns 95,004 shares of the company’s stock worth $377,000 after buying an additional 16,800 shares in the last quarter. Finally, Barclays PLC purchased a new position in shares of Rockwell Medical in the third quarter worth $90,000. Hedge funds and other institutional investors own 23.31% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.